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esophagusTo the Editor,
Esophageal small cell neuroendocrine carcinoma (SCNEC) is
extremely rare, representing 0.04e4.6% of all gastrointes-
tinal neuroendocrine neoplasms (NENs) and 1e2.8% of
esophageal cancers [1,2].
A 48-year-old female suffered from dysphagia and
foreign body sensation. An initial diagnosis was a 3.3 cm Figure 1. A 48-year-old female. (A) Endoscopy reveals an elevated
(B) Positron emission tomography/computed tomography revealed
esophagus. Resected surgical specimen. (C) The tumor cells have scan
nucleoli (hematoxylineeosin stain, original magnification 400). (D) T
(original magnification, 400). (E) More than 20% of the nuclei are po
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esophagus and locoregional metastatic lymphadenopathy
based on gastrointestinal endoscopy and positron
emission tomography/computed tomography (PET/CT;
Fig. 1). Total esophagogastrostomy and bypass, wedge
resection of the right lung, and right radical neck
dissection were performed. Esophageal specimens
revealed invasion of a small cell carcinoma into thesubmucosal mass covered with normal mucosa in the esophagus.
fluorodeoxyglucose accumulation in the lesion of the middle
t cytoplasm, hyperchromatic nuclei, and absent or inconspicuous
he scattered tumor cells show positive staining for synaptophysin
sitive for Ki-67 (original magnification, 400).
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Letter to the Editor 109muscularis propria and lymphovascular structure. Immu-
nohistochemical staining showed positive for cytokeratin
(CK), neuron-specific enolase (NSE), synaptophysin, CD56,
and Ki-67 > 20%. Pathological diagnosis was esophageal
SCNEC, pathological stage pT2N1. In addition, the other
incidental 0.5 cm acinar (100%) minimally invasive
adenocarcinoma, histological Grade II, sat in the right
lower lobe of the lung. Unfortunately, she experienced
multiple metastases at the liver and lymph nodes of the
neck 1 year later. She received radiotherapy and refused
chemotherapy for further treatment.
NENs are defined as epithelial neoplasms with pre-
dominant neuroendocrine differentiation, arising
throughout the body. The histologic grading system of the
2010 World Health Organization (WHO) classification for
digestive system NENs divides them into low-grade (G1,
Ki67 < 2%), intermediate-grade (G2, Ki67 2e20%) neuro-
endocrine tumors, and high-grade (G3, Ki67 > 20%)
neuroendocrine carcinomas (NECs, large- or small-cell
type) [3]. SCNEC is indistinguishable from small cell lung
cancer (SCLC) in histological and immunohistochemical
features. To diagnose a tumor as SCNEC, it is essential to
identify typical small cell carcinoma histology and
immunohistochemical evidence of epithelial differentia-
tion. Although positive staining for neuroendocrine
markers is not necessary, it makes a supplementary
contribution to the diagnosis [3].
The optimal treatment for esophageal SCNEC has not
yet been established. The few reported cases have been
mostly treated by esophagogastrectomy [4]. However, the
outcome for esophageal SCNEC treated with surgery alone
is extremely poor due to a high likelihood of disease
recurrence, even following complete resection. The me-
dian survival of patients after resection was 3.1e20
months [1]. Based on the similarity, both in behavior and
histopathological characteristics of SCLC, combined
chemotherapy with platinum-based doublets and etopo-
side, one of the standard regimens employed for the
treatment of SCLC, has been used widely for the treat-
ment of extrapulmonary SCNEC [2]. Other alternative
chemotherapy regimens based on amrubicin, oxaliplatin,
capecitabine, or taxanes have been reported [5]. How-
ever, most patients eventually relapse after chemo-
therapy and have a poor prognosis. Radiotherapy alone is
insufficient to improve the survival of SCNEC. However, a
multidisciplinary treatment approach consisting of resec-
tion, chemotherapy, and radiation therapy is recom-
mended for the treatment of extrapulmonary SCNEC
according to the National Comprehensive Cancer Network
(NCCN) guidelines for SCLC [3].References
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